MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2023: Top 20 Genomics Companies in the World
Verve Therapeutics, Inc. (NASDAQ: VERV)*
Organization & Developments: Verve
Parents
Verve Therapeutics, Inc. (NASDAQ: VERV)*
Children
*Verve Therapeutics is a genetic medicines company, developing an approach to cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines
*Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease
2022: Edits to a cholesterol gene could stop the biggest killer on earth_www.technologyreview.com
2022: Gene editing for heart disease: Verve kicks off landmark base editing trial
2022: Verve Therapeutics (VERV) Investor Presentation - Slideshow_seekingalpha.com
2022: Verve_Edits to a cholesterol gene could stop the biggest killer on earth
2022: Verve's momentum slows as high cholesterol gene editing therapy placed on hold by FDA
2023: Verve: Potential To Advance Gene Based Editing Drugs For ASCVD_ seekingalpha.com
2024: Vectoring In On Verve Therapeutics_ seekingalpha.com
2024: Verve pauses base editing trial, shifts strategy after treatment side effect
2024: Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
2024: Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
2024: Verve Therapeutics: An Update On Human CRISPR
2024: Verve Therapeutics: Cutting-Edge Science But Highly Risky Stock
2024: Verve Therapeutics’ (VERV) Gene-Editing Therapies Could Be a Game Changer
2024: Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
2025: Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2
Jumps
Finance & Acquisitions: Verve
Key People: Verve